Log In
Print
BCIQ
Print
Print this Print this
 

Nalbuphine ER (T111)

  Manage Alerts
Collapse Summary General Information
Company Endo International plc
DescriptionExtended-release oral formulation of nalbuphine, a mu opioid receptor (OPRM1; MOR) antagonist and kappa opioid receptor agonist
Molecular Target Mu opioid receptor (OPRM1) (MOR) ; Kappa opioid receptor (OPRK1) (KOR)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationItch
Indication DetailsTreat chronic uremic pruritus; Treat hemodialysis-related uremic pruritus
Regulatory Designation

Partner

Trevi Therapeutics Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today